The precise regulation of the cell cycle is fundamental to maintaining genomic stability and preventing diseases such as cancer. Central to this process are cyclin-dependent kinases (CDKs), whose activity is tightly controlled by their regulatory subunits, including cyclin A. Cyclin A levels rise at the onset of S phase and remain elevated until early mitosis, where they are rapidly degraded to permit mitotic exit. This degradation is crucial for timely progression through metaphase and anaphase transition. While the ubiquitin-proteasome system and APC/C-Cdc20 have long been recognized as key players in cyclin A destruction, emerging evidence highlights the importance of post-translational modifications—particularly acetylation—in regulating its stability.

We previously demonstrated that acetylation of cyclin A by PCAF and GCN5 at specific lysine residues (K54, K68, K95, and K112) marks it for degradation during prometaphase. Here, we identify histone deacetylase 3 (HDAC3) as a critical counter-regulator of this process. HDAC3 directly interacts with cyclin A via its N-terminal domain (residues 1–171), a region essential for both protein stability and degradation. This interaction occurs predominantly during G1/S and G2/M phases, when cyclin A is active and must be protected from premature acetylation-induced turnover.

Functional studies reveal that HDAC3 knockdown leads to a significant reduction in cyclin A protein levels without affecting cyclin A mRNA expression. This indicates that HDAC3 regulates cyclin A at the post-translational level rather than transcriptionally. The decrease in cyclin A is accompanied by increased acetylation, confirming that HDAC3 maintains cyclin A in a hypoacetylated, stable state. Furthermore, proteasome inhibition rescues cyclin A levels in HDAC3-depleted cells, demonstrating that the degradation is proteasome-dependent.

Importantly, HDAC3 itself undergoes rapid degradation during mitosis via the proteasome, coinciding with the timing of cyclin A destruction. This suggests a temporal switch: as HDAC3 levels decline, the balance shifts toward acetylation, allowing PCAF/GCN5 to modify cyclin A and initiate its degradation. This coordinated removal of HDAC3 ensures that cyclin A is only destabilized at the correct stage of mitosis.

Consequently, depletion of HDAC3 disrupts normal cell cycle progression. Flow cytometry analysis shows a marked accumulation of cells at both S phase and G2/M transition, consistent with reduced cyclin A levels impairing CDK activation required for S phase completion and mitotic entry. Synchronized experiments further confirm that HDAC3-deficient cells exhibit delayed progression through G1/S and G2/M phases, underscoring its role in enabling timely cell cycle transitions.Drospirenone site

These findings position HDAC3 not merely as a chromatin modifier but as a direct regulator of a core cell cycle component.TMEM119 ProteinSource By modulating cyclin A acetylation, HDAC3 ensures that cyclin A remains stable until the appropriate moment for degradation.PMID:35226851 This mechanism provides a dynamic and reversible control point that integrates metabolic and signaling cues into the cell cycle engine. The discovery of HDAC3’s role in cyclin A regulation reveals a new dimension of cell cycle control—one governed by the opposing actions of acetyltransferases and deacetylases—and highlights potential therapeutic targets for diseases characterized by aberrant cell proliferation.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Renal cell carcinoma (RCC) remains a significant clinical challenge due to its resistance to conventional therapies and frequent metastatic spread. Recent advances in molecular oncology have highlighted the critical role of microRNAs in regulating tumor progression. Among these, let-7d has emerged as a potential tumor suppressor in RCC. This study demonstrates that let-7d is significantly downregulated in human RCC tissues and cell lines, correlating with advanced tumor stage, higher grade, vascular invasion, and increased macrophage infiltration. Functional assays reveal that overexpression of let-7d markedly inhibits RCC cell proliferation, migration, and monocyte recruitment in vitro. In vivo models using xenografts confirm that let-7d overexpression suppresses primary tumor growth, lung metastasis, and tumor-associated macrophage infiltration.2-Amino-N-hydroxybenzamide site Comprehensive bioinformatics and experimental validation identify collagen type III alpha 1 (COL3A1) and C-C chemokine ligand 7 (CCL7) as direct targets of let-7d.1,2,6-Hexanetriol Protocol Both genes are upregulated in RCC tissues and inversely correlate with let-7d expression levels.PMID:35234296 Rescue experiments show that exogenous COL3A1 and CCL7 counteract the anti-tumor effects of let-7d, confirming their functional relevance. Furthermore, inhibition of let-7d in low-metastatic OS-RC-2 cells increases COL3A1 and CCL7 expression, enhancing cell proliferation, migration, and chemotaxis—effects reversed by CCL7 neutralizing antibody. These findings establish a mechanistic link between let-7d and tumor microenvironment modulation via COL3A1 and CCL7. The data suggest that restoring let-7d function may represent a promising therapeutic strategy for suppressing RCC progression and metastasis, particularly by disrupting stromal remodeling and macrophage recruitment. This work underscores the importance of miRNA-mediated regulation in cancer biology and highlights let-7d as a potential biomarker and target for future RCC therapies.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Shigella flexneri remains a leading cause of shigellosis in developing nations, primarily due to its ability to evade host immune responses through antigenic variation. The bacterium’s surface lipopolysaccharide (LPS) contains a highly variable O-antigen that serves as the basis for serotyping. All serotypes except serotype 6 share a common tetrasaccharide repeat backbone composed of one N-acetylglucosamine (GlcNAc) and three rhamnose residues: RhaI, RhaII, and RhaIII. This basic structure forms the foundation for serological diversity, which arises from various modifications including glucosylation, O-acetylation, and phosphoethanolamine (PEtN) addition. These modifications generate distinct antigenic determinants—designated group factors—that define the current serotyping system. Recently, a novel modification has been identified: the addition of an O-acetyl group to position 3 or 4 of Rhamnose III (3/4-O-acetylation), observed in serotypes 1a, 1b, 2a, 5a, Y, and 6. This modification is mediated by the oacB gene, which is functional in serotypes 1a, 1b, 2a, 5a, and Y but not in serotype 6, where a different acyltransferase, oacC, appears to be responsible.Surfactin Purity

In this study, we investigated the distribution and immunological significance of 3/4-O-acetylation across S.Ivacaftor manufacturer flexneri isolates.PMID:35157880 PCR screening of the oacB gene in 730 clinical isolates revealed widespread presence in serotypes 1a, 1b, 2a, 5a, and Y, with positive rates of 95.33%, 100%, 96.45%, 64.29%, and 64.10%, respectively. Notably, mutations in oacB—including insertions, deletions, and point mutations—were found in several strains, particularly among serotypes 2b, X, and Xv, explaining their lack of functional 3/4-O-acetylation. To detect the resulting antigenic determinant, we developed a specific rabbit antiserum (grouping antiserum 9) using a recombinant strain (51251_pSQZ4) expressing the modification and absorbing against the non-modified parent strain (51251). Serological assays demonstrated that antiserum 9 reacted exclusively with strains possessing functional oacB and 3/4-O-acetylated RhaIII, confirming the specificity of the epitope.

Further structural analysis via NMR spectroscopy of O-polysaccharides from O factor 9-negative strains (05135, 07HN194, M90T) confirmed the absence of O-acetyl groups on RhaIII, despite identical backbone structures to their positive counterparts. This provides direct chemical evidence that the 3/4-O-acetylation defines a unique antigenic determinant. Antiserum 9 agglutinated 382 out of 730 isolates (52.33%), predominantly in serotypes 1a, 1b, 2a, 5a, Y, and 6. The high prevalence of this epitope in endemic regions such as China suggests it may contribute to immune evasion or transmission fitness. Importantly, no cross-reactivity was observed with other Shigella or Escherichia coli serogroups, confirming the specificity of antiserum 9.

These findings establish that 3/4-O-acetylation of RhaIII confers a previously unrecognized antigenic determinant, provisionally named Group O Factor 9. Its detection enables finer differentiation within existing serotypes and offers new tools for epidemiological surveillance and vaccine development. We propose incorporating Group O Factor 9 into the current serotyping scheme, enabling more precise classification of S. flexneri isolates. The availability of grouping antiserum 9 enhances diagnostic accuracy and supports global efforts to track emerging variants and improve public health interventions.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

The present study aimed to investigate the composition and potential anticancer activities of essential oils obtained from two species, myrrh and frankincense, by hydrodistillation. Using gas chromatography-mass spectrometry (GC-MS), 76 and 99 components were identified in the myrrh and frankincense essential oils, respectively, with the most abundant components, 2-Cyclohexen-1-one, 4-ethynyl-4-hydroxy-3,5,5-trimethyl- and n-Octylacetate, accounting for 12.01% and 34.66%, respectively. The effects of the two essential oils, independently and as a mixture, on five tumor cell lines—MCF-7, HS-1, HepG2, HeLa, and A549—were investigated using the MTT assay. Results indicated that the MCF-7 and HS-1 cell lines showed increased sensitivity to the myrrh and frankincense essential oils compared to the other cell lines. Furthermore, the anticancer effects of myrrh were markedly stronger than those of frankincense; however, no significant synergistic effects were observed when the oils were combined. Flow cytometry analysis revealed that apoptosis may be a major mechanism underlying the biological efficacy in MCF-7 cells.

Commiphora myrrha produces a yellow oleo-gum resin used globally for myrrh production, particularly in China and Egypt. Its constituents include volatile oil (2–8%), resin (23–40%), gum (40–60%), and bitter principles (10–25%). Previous research has demonstrated that myrrh exhibits cytotoxic, analgesic, anti-inflammatory, anticancer, antiparasitic, and hypolipidemic properties. Frankincense, derived from Boswellia trees, is known for its aromatic resin and has been associated with health benefits such as treating rheumatoid arthritis and demonstrating anti-inflammatory, antibacterial, antifungal, and anticancer activities. Frankincense oil is typically prepared via steam distillation and widely used in aromatherapy. The composition of frankincense oil varies depending on climate, harvest conditions, and geographical origin. Notably, myrrh and frankincense are frequently prescribed together in traditional Chinese medicine for blood stagnation, inflammation, swelling, and pain relief. A prior study reported synergistic antimicrobial effects between frankincense and myrrh oils against Cryptococcus neoformans and Pseudomonas aeruginosa. This study focused on the chemical profile of hydrodistilled frankincense and myrrh oils from Ethiopia and evaluated their anticancer potential against MCF-7, HepG2, HeLa, HS-1, and A549 cell lines to assess possible synergistic interactions in vitro.

Dry sap samples were collected from the stem bark of Boswellia carterii and Commiphora pyracanthoides Engler in August 2009 in Ethiopia. The plant materials were authenticated by a botanist at Harbin Medical University-Daqing, with voucher specimens retained in the Department of Pharmacology. Essential oils were extracted through hydrodistillation after freezing the dried samples for 24 hours. Thirty grams of each powdered sample underwent 3-hour hydrodistillation following the AB method. The resulting oils were diluted with 1% Tween 80 for bioactivity testing. A 1:1 mixture of both oils was also prepared. GC-MS analysis was conducted using an Agilent Technologies GC-MS system coupled with a Shimadzu QP2010S mass spectrometer. A Rtx®-50 capillary column (30×0.25 mm, 0.25 µm) was used with helium as carrier gas. The injector temperature was set at 230°C, and the interface and ion source temperatures were 300°C and 230°C, respectively. The temperature program started at 60°C for 1 minute, then increased to 220°C at 5°C/min and held for 15 minutes. Column head pressure was maintained at 70 kPa, electron ionization mode at 70 eV, and scan range from 20 to 500 amu with a cycle time of 0.65 seconds. Mass spectral data were matched against the NIST05 database.

Human cancer cell lines—including breast (MCF-7), hepatocellular (HepG2), cervical (HeLa), skin (HS-1), and lung (A549)—were obtained from the American Type Culture Collection. Cells were cultured in monolayer dishes using RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine. Cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂. For the MTT assay, 5×10³ cells per well were seeded into 96-well plates and allowed to adhere overnight. Cells were then treated with varying concentrations (0, 5, 10, 20, 40, 60, 80, 160, 180, 320, 640 µg/ml) of frankincense, myrrh, or their mixture for 24 and 48 hours. After incubation, 20 µl of MTT solution (5 mg/ml in PBS) was added to each well and incubated at 37°C for 4 hours. Formazan crystals were dissolved in 100 µl dimethyl sulfoxide, and absorbance was measured at 570 nm using a microplate reader. IC₅₀ values were calculated as the concentration causing 50% inhibition of cell viability using SlideWrite software.

Synergistic effects were assessed using isobologram analysis based on Loewe additivity. The equation IC₅₀(A+B) = DA/ICₓ,A + DB/ICₓ,B was applied, where IC₅₀(A+B) represents the combination concentration required for 50% inhibition, ICₓ,A and ICₓ,B denote individual drug concentrations for 50% inhibition, and DA and DB indicate the respective mixture concentrations achieving the same effect. Isobolograms were plotted with predicted doses of A vs B, including a line of additivity. Points below the line suggest synergy, while those above indicate antagonism. Apoptosis was quantified via flow cytometry.Benzylmethyl ether MedChemExpress MCF-7 cells (1×10⁶) were treated with 0, 10, 20, and 40 µg/ml of either essential oil or their mixture for 24 and 48 hours. Cells were harvested by trypsinization, washed with cold PBS, and stained with Annexin V-FITC and propidium iodide (PI).1-Acetyl-2-imidazolidinone custom synthesis After 20-minute incubation in the dark, cells were resuspended in PBS binding buffer and analyzed within 30 minutes using a BD FACSAria flow cytometer.PMID:34533957

GC-MS analysis revealed that myrrh essential oil yielded approximately 0.41 ml (2.05%, ml/g), while frankincense produced 0.62 ml (2.06%, ml/g). Seventy-six compounds accounted for 87.54% of the total myrrh oil, and 99 compounds made up 91.26% of frankincense oil. The MTT assay showed dose-dependent growth inhibition across all tested cell lines. Among them, MCF-7 and HS-1 cells exhibited the highest sensitivity to both essential oils. The IC₅₀ values at 24 hours were lowest for MCF-7 (19.8 µg/ml for myrrh, 40.7 µg/ml for frankincense), followed by HS-1 (22.7 µg/ml, 39.7 µg/ml). In contrast, HepG2, HeLa, and A549 showed higher resistance. Isobologram analysis showed all data points lying above the Loewe additivity line, indicating no synergistic effect. Flow cytometry confirmed that both oils induced apoptosis in MCF-7 cells in a concentration-dependent manner. At 40 µg/ml, the early and late apoptotic rates were 36.0% (myrrh), 77.3% (frankincense), and 45.8% (mixture), significantly higher than controls (P < 0.01). In conclusion, myrrh essential oil demonstrates superior anticancer activity compared to frankincense, particularly against breast and skin cancer cell lines. Apoptosis appears to be a key mechanism of action. Despite their historical use together in traditional medicine, no synergistic effect was observed in this in vitro model. Further studies are needed to explore the roles of specific constituents like -elemene and n-octyl acetate in antitumor activity and to validate these findings in vivo.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Peritoneal adhesions remain a significant clinical challenge following abdominal surgery, contributing to chronic pain, bowel obstruction, and increased surgical complexity in subsequent procedures. This prospective, multi-center, randomized, single-blind study evaluated the SprayShield™ Adhesion Barrier System—a sprayable PEG ester amine and buffer solution formulation—for its potential in reducing postoperative adhesion formation. A total of 11 patients diagnosed with ulcerative colitis or familial adenomatous polyposis underwent restorative proctocolectomy with ileal J-pouch-anal anastomosis and diverting loop ileostomy. Eight patients were assigned to the SprayShield™ group, while three received standard surgical care without any adhesion barrier (control group). The barrier was applied directly under the midline incision and at the ileostomy site using an air-assisted sprayer, enabling even coverage and visual confirmation due to the blue colorant.

At follow-up surgery (10–12 weeks later), adhesions were assessed for incidence, severity, extent, and impact on surgical mobilization time. The primary endpoint was the presence of adhesions at the midline incision. Results showed that adhesion incidence was lower in the SprayShield™ group (37.5%) compared to controls (66.7%), with mean severity scores of 0.9 versus 1.3, respectively. Although not statistically significant, these trends suggest a potential benefit. Additionally, the mean time required to mobilize the ileal loop during reversal surgery was slightly shorter in the SprayShield™ group (41.0 minutes) than in the control group (43.3 minutes). However, a higher proportion of patients in the SprayShield™ group developed adhesions around the ileostomy site (75% vs.4-(Triethylsilyl)but-3-yn-1-ol custom synthesis 66.7%), and the total reversal procedure time was longer (100.6 min vs. 89.0 min), possibly due to procedural variability or technical factors.

Safety assessments revealed five mild adverse events across both groups—leukocytosis, impaired healing, urinary tract infection, surgical skin tear, and elevated hepatic enzymes—and two severe events: dehydration and fasciitis.Tetrahydrofuryl alcohol Technical Information No device-related serious adverse events were reported, and no residual material from SprayShield™ was detected at second-look laparoscopy.PMID:34792767 All investigators found the product easy to apply, with median application time of 8.5 minutes, and noted excellent adherence and conformity to irregular surfaces.

Despite the promising safety profile and ease of use, the small sample size limited statistical power, preventing definitive conclusions about efficacy. The study was terminated early due to funding constraints, not safety or lack of effectiveness. While the results indicate a possible reduction in midline adhesion formation and improved mobilization time, larger, well-powered trials are essential to confirm these findings. SprayShield™ demonstrates potential as a practical, safe, and effective adjunct in adhesion prevention, particularly in complex colorectal surgeries where tissue trauma is extensive. Further research is warranted to validate its role in improving long-term surgical outcomes.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com